The adenosine analogue Galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has 20 entered a Phase 1 clinical safety and pharmacokinetics study in healthy subjects and is under 21 clinical development for treatment of Ebola virus infection. Moreover, Galidesivir also 22 inhibits the reproduction of tick-borne encephalitis virus (TBEV) and numerous other 23 medically important flaviviruses. Until now, studies of this antiviral agent have not yielded 24 resistant viruses. Here, we demonstrate that an E460D substitution, in the active site of 25 TBEV RNA-dependent-RNA-polymerase (RdRp), confers resistance to Galidesivir in cell 26 culture. Stochastic molecular simulations indicate that the steric freedom caused by the 27 E460D substitution increases close electrostatic interactions between the inhibitor and the 28 interrogation residue of the TBEV RdRp motif F, resulting in rejection of the analogue as an 29 incorrect/modified nucleotide. Galidesivir-resistant TBEV exhibited no cross-resistance to 30 structurally different antiviral nucleoside analogues, such as 7-deaza-2´-C-methyladenosine, 31 2´-C-methyladenosine and 4'-azido-aracytidine. Although, the E460D substitution led only to 32 a subtle decrease in viral fitness in cell culture, Galidesivir-resistant TBEV was highly 33 attenuated in vivo, with 100% survival rate and no clinical signs observed in infected mice. 34
on the host cells (Eyer et al., 2017a) . A Phase 1 clinical safety and pharmacokinetics study in 87 healthy subjects has been completed, and at present, Galidesivir is under clinical 88 development as an antiviral drug for treatment of Ebola virus infection (Taylor et al., 2016) . 89
The broad-spectrum antiviral activity makes this drug a promising candidate for 90 development of therapy not only for Ebola virus infection but also other important diseases 91 caused by various RNA viruses, including TBEV. 92
Although Galidesivir has been studied intensively and is known to inhibit a wide 93 range of RNA viruses, there are no published reports of resistance to this compound. 94
Experience with the treatment of other RNA virus infections shows, that resistance can 95 develop rapidly with any of the direct-acting antiviral agents (Poveda et al., 2014; Bagaglio et 96 al., 2017; Irwin et al., 2016) . Due to the low fidelity of viral RdRps in general, the mutation 97 frequency is estimated to be 10 −4 to 10 −6 errors per nucleotide (Lauring et al., 2013) . The 98 high mutation frequency and high replication rate of viral RNA copies enable the viruses 99 quickly to adapt to changes in the environment, including the introduction of antiviral drugs. 100
Identification of mutations conferring antiviral resistance provides information not only 101 6 efficient and specific antiviral therapies. In order to select TBEV resistant to Galidesivir, the 119 virus was serially passaged in PS cell monolayers in the presence of increasing 120 concentrations of Galidesivir up to 50 µM ( Figure 1B) ; this process resulted in selection of 121 two independent drug-resistant TBEV mutant strains. Whole genome sequencing of the 122 passaged viruses revealed, that both selected TBEV mutants carried a single amino acid 123 change E460D, which corresponds to the nucleotide substitution G9045T in the NS5 gene 124 ( Figure 1C,D) . Sequencing of viruses after each passage showed, that this mutation was 125 acquired after 5 passages. In passages 6 and 7, mixed mutated and wild-type genotypes 126 were detected; from passage 8 onwards, the mutated genotype dominated until the end of 127 the experiment (passage 9) ( Figure 1D ). Interestingly, in one of the selected TBEV mutants, 128 an additional amino acid change Y453H was detected; this mutation, which was acquired 129 after 8 passages, corresponds to the nucleotide substitution T9022C in the NS5 gene (Figure 130 In order to demonstrate the direct effect of the amino acid substitutions E460D and 142 Y453H on TBEV phenotype, the appropriate mutations were introduced into recombinant 143 TBEV strains generated by the rapid reverse genetic approach based on the use of 144 subgenomic overlapping DNA fragments (Aubry et al., 2014; Driouich et al, 2018) . The entire 145 TBEV strain Hypr genome flanked at the 5´and 3´untranslated regions by the pCMV and 146 HDR/SV40pA was de novo synthesized in three double stranded DNA fragments of 147 approximately 4.4, 4.5 and 3.1 kb in length, overlapping by 80 to 120 pb. The substitutions 148 E460D (G9045T) and Y453H (T9022C) were introduced into the NS5 gene located on 7 fragments into permissive BHK-21 cells, the following recombinant TBEV strains were 151 successfully rescued: E460D-Rec (E460D substitution in the NS5 gene), Y453H-Rec (Y453H 152 substitution in the NS5 gene), and recombinant wild-type (no introduced mutations). The 153 presence of the E460D and Y453H substitutions in the viral genomes was confirmed by 154 whole-genome sequencing of all recombinant viruses. Despite repeated attempts, the 155 E460D/Y453H-Rec mutant (both mutations E460D and Y453H in the NS5 gene) was not 156 rescued from the transfected BHK-21 cell culture. E460D-Rec was found to be 7.9-fold less 157 sensitive to Galidesivir than engineered wild-type, showing an EC50 value of 6.32 ± 1.01 µM 158 (Table 2) . On the other hand, Y453H-Rec was highly sensitive to Galidesivir; the replication of 159 this mutant strain was completely inhibited at 12.5 µM, showing an EC50 value of 0.81 ± 0.01 160 µM (Table 2) . Thus, the results indicate, that the E460D (not Y453H) substitution is solely 161 responsible for the drug-resistant phenotype of TBEV ( Figure 2A ). 162
163
The E460D mutation has only a moderate effect on TBEV replication in cell culture 164
To characterize the phenotypic properties of the drug-resistant mutant in vitro, 165 growth kinetics ( Figure 2B ) and plaque morphology ( Figure 2C ) of the recombinant TBEV 166 mutant E460D-Rec were assayed in cultures of PS cells and compared with the wild-type 167 virus. The wild-type virus amplified in the absence of Galidesivir ( Figure 2B , red line), showed 168 a short lag-period within intervals 0 -12 hours p.i. Starting 24 hours p.i., the wild-type TBEV 169 exerted an exponential increase in virus infectivity reaching a peak titre of 3x10 6 PFU/mL 170 within 72 hours p.i. and gradually declining thereafter. In contrast, the presence of 171 Galidesivir (25 µM) completely inhibited replication of the wild type virus ( Figure 2B , violet 172 line). 173
In comparison with the wild-type virus, the E460D-Rec mutant cultured in the 174 absence of Galidesivir ( Figure 2B , blue line) showed a prolonged lag-period within intervals 0 175 -36 hours p.i. However, subsequently, the infectivity of the mutant virus increased 176 exponentially reaching a peak of 2.6x10 6 PFU/mL at 72 hours p.i. After that, the titre 177 gradually declined to 5.5x10 4 PFU/mL. The considerably longer lag-period of the E460D-Rec 178 mutant could be explained by a slightly decreased replication capacity (attenuation) of the 179 mutant, when amplified in PS cell culture. The decrease in replication capacity of E460D-Rec 180 was manifested particularly in the first few hours after cell culture infection and was no 181 longer detecable in the later stages of the infection.
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The E460D-Rec mutant cultured in the prensence of Galidesivir (25 µM) ( Figure 2B , 183 green line) also exerted an extended lag-period within intervals 0 -36 hours p.i.; there was 184 even a moderate decrease in viral titers after 36 hours p.i. Starting 48 hours p.i., the mutant 185 showed an exponential infectivity and reached a peak titre of 3.9x10 5 PFU/mL at day 96 186 hours p.i. The results clearly indicate, that the resistance of TBEV to Galidesivir is only partial; 187 the growth of the mutant strain in the presence of Galidesivir was partially inhibited 188 compared to wild-type ( Figure 2B , red line) or the E460D-Rec mutant grown in the absence 189 of Galidesivir ( Figure 2B , blue line). 190
The plaque morphology of the drug-resistant TBEV mutant was similar to that of wild-191 type virus; both viruses produced large and clear plaques which were round and regular in 192 shape and did not change in shape and size during all the consecutive passages ( Figure 2C ). 193
The similarity in plaque morphology of drug-resistant and wild-type TBEVs is in agreement 194 with similar growth kinetics of both viruses and supports our assumption that the mutation 195 E460D affects the viral replication in PS cell culture only to a limited extent. 196
197
The E460D TBEV mutant is sensitive to 7-deaza-2´-C-methyladenosine, 2´-C- Mouse neuroinvasiveness of the E460D TBEV mutant is highly attenuated 212
The degree of neuroinvasiveness of the E460D TBEV mutant was assessed in BALB/c subcutaneously with 10 3 PFU of either virus and survival rates and clinical signs of 215 neuroinfection were monitored for 28 days. Wild-type virus produced fatal infections in all 216 mice, with mean survival times of 11 ± 2.2 days; infected mice showed severe signs of 217 disease, such as ruffled fur, hunched posture, tremor and hind leg paralysis ( Figure 3A In general, mutant genotypes rapidly revert to the wild-type in the absence of the 227 selection agents. Indeed, after three passages in PS cells in the absence of Galidesivir a pool 228 comprising mutated and wild-type genotypes was detected. Moreover from passage 5 229 onwards, the wild-type genotype dominated in the infected PS cell culture ( Figure 1E ). 230
Interestingly, the codon GAT encoding an aspartic acid in the E460D mutant had changed to 231 the codon GAA in the revertant, not to GAG as seen in mock-selected wild-type virus; both 232 codons, GAA (in the revertant) and GAG (in the wild-type), are synonymous and encode a 233 glutamic acid residue ( Figure 1F ). In contrast, after 6 passages in the presence of Galidesivir, 234 at concentrations up to 25 µM, the E460D substitution was retained; even at low 235 concentrations of Galidesivir (6.25 µM) and did not result in reversion to the wild-type 236 genotype (data not shown). 237
238
Galidesivir migration towards the TBEV RdRp active site 239
The deduced position of Galidesivir bound within the TBEV RdRp active site is shown 240 in Figure 4A with its phosphate tail forming close contacts with the manganese cofactors. 241
The E460D (and Y453H) mutation is located at motif F of the flavivirus RdRp finger domain. 242
The flavivirus RdRp motif F is highly flexible and occludes the NTP-tunnel in the nucleotide 243 bound RdRp structure (Valdés et al., 2016) . Therefore, the apo-structure was used for 244 stochastic simulations to compare and contrast how Galidesivir approaches the TBEV active 245 site in the wild type and mutant RdRps. At the active site of the wild type TBEV RdRp, the 246 ribose of Galidesivir is at a 5.7 Å distance from amino acid (aa) position 460. The missing 247 carbon in Asp increases this distance (7 Å) compared to Glu. This increased distance, caused 248 by the mutation, results in more steric freedom for Galidesivir as it approaches the active 249 site ( Figure 4B,C) . 250
There is a ~6.7 Å distance cutoff by Galidesivir approaching the wild type TBEV RdRp 251 active site that is explored closer (<5 Å) in both mutant types ( Figure 4B ). The single RdRp 252 mutation, E460D, however, has lower enthalpic ligand binding values compared with the 253 double mutant, E460D/Y453H. These lower enthalpic values indicate a favorable ligand 254 binding and conformation. The distinct differences in Galidesivir exploration between the 255 wild type and mutant RdRps are shown by the average COM distance/enthalpy in Figure 4B were cultured at 37 °C with 5% CO2 in Minimal Essential Medium (MEM) containing 7% 387 ( Figure 4) . Fragment III was used as template to generate by PCR two overlapping amplicons 439 following the original ISA method (Aubry et al., 2014) . Unmodified primers were used to 440 generate two unmodified amplicons (i.e. production of wild-type virus). Mutated primers 441 located on the targeted region were used to generate two mutated amplicons (i.e. 442 production of mutated viruses, denoted as E460D-Rec, Y453H-Rec, and E460D/Y453H-Rec) 443 (Table 1, Figure 4 ). 444
The PCR was performed using the Platinum SuperFI PCR Master Mix (Thermo Fisher 445 Scientific, Prague, Czech Republic). The mixture (final volume, 50 μl) contained 45 μL of 446 SuperMix, 2 μl of DNA template (fragment III) at 1 ng/μl. Assays were performed on a 447
Biometra TProfessional Standard Gradient thermocycler with the following conditions: 94 °C 448 for 2 min followed by 40 cycles of 94 °C for 15 s, 60 °C for 30 s, 68 °C for 5 min and a final 449 elongation step of 68 °C for 10 min. Size of the PCR products was verified by gel 450 electrophoresis and purified using an Amicon Ultra 0.5 ml kit (Millipore). 451
An equimolar mixture of these four DNA fragments was used for cell transfection. 
Mouse infections 486
To evaluate the virulence of the Hypr E460D mutant in mice, four groups of six-week 487 old BALB/c female mice (purchased from AnLab, Prague, Czech Republic) were infected 488 subcutaneously with TBEV (1,000 PFU/mouse) as follows: group 1 (n = 10), infected with in 489 vitro mock-selected wild-type; group 2 (n = 10), infected with in vitro selected mutant
The unbound, apo-form of the TBEV RdRp used in this study is a homology-based 502 predicted structure previously prepared for simulations in other published studies (Valdés et 503 al., 2016 (Valdés et 503 al., , 2017 . The stochastic molecular simulations were conducted using the online 504 software, Protein Energy Landscape Exploration (PELE) that employs a Metropolis Monte 505 Carlo algorithm which accepts or rejects a protein-ligand conformation based on its 506 enthalpy. The PELE method and its applications are thoroughly explained online 507 The reverse genetics method used in this study was based on the generation of infectious 707 subgenomic overlapping DNA fragments that encompass the entire viral genome. Three de 708 novo synthesized DNA fragments cloned into a pUC57 vector were used. The first and last 709 fragment were flanked respectively in 5´and 3´with the human cytomegalovirus promoter 710 (pCMV) and the hepatitis delta ribozyme followed by the simian virus 40 polyadenylation 711 signal (HDR/SV40pA). Fragments I and II were generated using the SuPReMe method: 712 plasmids were digested using restriction enzymes. Fragment III was used as template to 713 generate by PCR two overlapping amplicons following the original ISA method. Unmodified 714 primers were used to generate two unmodified amplicons (i.e. production of wild-type 715 virus). Mutated primers located on the targeted region were used to generate two mutated 716 amplicons (green and blue squares represent respectively mutations G9045T and T9022C). 717
An equimolar mix of these four DNA fragments was used to transfect BHK-21 cells. 718 Table 1 . Unmodified and mutated primers used to generate two overlapping amplicons of 720 fragment III (fragment IIIa and IIIb), i.e. to produce recombinant wild-type and mutated Table 2 . Inhibitory properties of Galidesivir for the obtained TBEVs 726
Virus
Method to generate wild-type/mutated virus EC50 [µM]* (fold increase compared to wild-type value) E460D
In vitro selection (passaging in PS cells) 6.66 ± 0.04 (7.01) E460D/ Y453H 7.20 ± 0.09 (7.57) wild type 0.95 ± 0.04 E460D-Rec Reverse genetics 6.32 ± 1.01 (7.90) Y453H-Rec 0.81 ± 0.01 (1.01) E460D/ Y453H-Rec not rescued wild-type-Rec 0.80 ± 0.01 *Determined from three independent experiments. Expressed as a 50% reduction of viral titers and 727 calculated according to the Reed-Muench method. PS cells were infected with the virus (MOI of 0.1) 728 and cultivated at Galidesivir concentrations ranging from 0 to 50 µM for three days.
